Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ArcelorMittal SA (MT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ArcelorMittal SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while ArcelorMittal SA trades at $66.55 (market cap $49.99B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and ArcelorMittal SA pays a 0.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MT | |
|---|---|---|
Market Cap | $39.89B | $49.99B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $71.65 |
52-Week Low | $278.09 | $30.39 |
Enterprise Value | $38.15B | $59.31B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ArcelorMittal (MT) trades at $66.08, up 4.96% today, with strong earnings beats in recent quarters. The stock shows bullish momentum with a 41% gain over six months, supported by record iron ore shipments and strategic expansions. Valuation ratios appear reasonable with P/E at 17.3 and P/B below 1. Technical indicators are mixed, with moving averages bullish but oscillators neutral. Recent news highlights CEO transitions in Europe and a new share buyback program.
Outlook remains positive due to operational strength and shareholder returns, but risks include heavy capital expenditure and China demand weakness. Analyst consensus is bullish with 50% buy ratings. The stock's performance hinges on continued execution amid global steel market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
